What premedication should be administered before a rituximab infusion?

Rituximab Premedication

Premedicate all patients receiving rituximab with acetaminophen (paracetamol) and an antihistamine (such as diphenhydramine) before each infusion. 1

Standard Premedication Protocol

Core Premedication (All Patients)

• Acetaminophen (paracetamol): 650-1000 mg orally 2
• Antihistamine: Diphenhydramine 25-50 mg (or equivalent) orally or intravenously 2, 1
• Timing: Administer 30-60 minutes before rituximab infusion 1

Disease-Specific Corticosteroid Requirements

For Rheumatoid Arthritis, GPA/MPA, and Pemphigus Vulgaris patients:

• Methylprednisolone 100 mg IV (or equivalent) is recommended 30 minutes prior to each infusion 1

For Oncology patients (NHL, CLL):

• Corticosteroids are typically given as part of the chemotherapy regimen (e.g., R-CHOP) and should be administered prior to rituximab 1
• If rituximab is given as monotherapy without a chemotherapy regimen containing steroids, consider adding corticosteroid premedication based on risk assessment 3

For Pediatric GPA/MPA patients:

• Intravenous methylprednisolone 30 mg/kg (not to exceed 1g/day) once daily for 3 days prior to the first rituximab infusion 1

Clinical Context and Rationale

High Risk of Infusion Reactions

Rituximab carries a 77% incidence of infusion reactions on the first infusion, with severe reactions occurring in 10% of patients 2. The incidence dramatically decreases with subsequent infusions to 3-8% 3. This high first-dose reaction rate is attributed to cytokine release from B-lymphocyte destruction 2.

Evidence for Corticosteroid Premedication

Corticosteroid premedication significantly reduces severe infusion reactions. In patients receiving corticosteroid premedication for their first infusion, the incidence of infusion reactions was only 8.3% compared to 41.2% in those without corticosteroid premedication (p=0.017) 3. This represents a nearly 5-fold reduction in reaction risk.

Alternative Antihistamine Options

Recent evidence suggests second-generation antihistamines may be superior to first-generation agents:

• Rupatadine and montelukast combinations reduced infusion reaction rates from 75% (standard premedication) to 22% when both agents were used together 4
• These regimens also decreased infusion time, reaction severity, and need for rescue medications 4
• Bepotastine besilate (second-generation) is being compared to hydroxyzine (first-generation) in ongoing trials 5

Common Pitfalls and Caveats

Timing Matters

• Premedication must be given with adequate lead time (30-60 minutes) to achieve therapeutic levels before rituximab infusion begins 1
• Starting the infusion too soon after premedication administration increases reaction risk

High Tumor Burden Patients

• Patients with high circulating lymphocyte counts (>25 × 10⁹/L) are at higher risk for severe cytokine release syndrome 2
• Consider split dosing over 2 days during the first cycle for these high-risk patients 2
• Use a reduced infusion rate for the first infusion in patients with high tumor burden 2

Subsequent Infusions

• While the FDA label recommends premedication before each infusion 1, the risk decreases substantially after the first dose 3
• Some centers safely use accelerated infusion protocols (30-90 minutes) for subsequent doses with standard premedication 6, 7
• Do not become complacent—reactions can still occur on later infusions, though less frequently 2

Pediatric Considerations

• Pediatric patients with mature B-cell NHL/B-AL should receive prednisone as part of their chemotherapy regimen prior to rituximab during induction 1
• H1 antihistamine (diphenhydramine or equivalent) should be given 30-60 minutes before infusion 1